Anticoagulant effects of edoxaban in healthy volunteers and patients with cirrhosis. (A) Endogenous thrombin potential (ETP), (B) D-dimer levels, and (C) edoxaban-calibrated anti-Xa levels at baseline and in samples taken at 3 time points during administration of 60 mg edoxaban once daily to 16 patients with cirrhosis and 16 healthy controls. Horizontal lines represent medians. Values in patients and controls at a single time point were compared using Student t test or Mann-Whitney U test as appropriate. The Wilcoxon signed-rank test was used to assess differences between time points within a single group. #P < .05 vs controls; +P < .05 vs baseline.